Global Information
회사소개 | 문의 | 비교리스트

시장 스포트라이트 : 육종

Market Spotlight: Sarcoma

리서치사 Datamonitor Healthcare
발행일 2021년 05월 상품코드 939994
페이지 정보 영문 48 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 1,318 ₩ 1,905,000 PDF (Single User License)


시장 스포트라이트 : 육종 Market Spotlight: Sarcoma
발행일 : 2021년 05월 페이지 정보 : 영문 48 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 육종 치료제 시장에 대해 조사분석했으며, 주요 출시약·파이프라인약, 임상시험, 최근 동향, 향후 동향, 성공 확률, 특허 정보, 10년 예측 등에 관한 정보를 정리하여 전해드립니다.

목차

개요

요점

질환의 배경

  • 서브타입

치료

  • 수술
  • 화학요법
  • 방사선 치료
  • 표적치료

역학

  • 역학적 질환의 정의

출시약

파이프라인약

최근 동향과 애널리스트의 견해

향후 동향

주요 규제의 동향

성공 확률

라이선스와 자산 인수 거래

모특허

매출 기회

임상시험 상황

  • 스폰서 : 현황별
  • 스폰서 : 단계별
  • 최근 동향

참고 문헌

  • 처방 정보

부록

KSA 20.06.17

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were approximately 430,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 503,700 incident cases by 2028.

Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (85%), while a smaller proportion were osteosarcomas and malignant bone tumors (15%).

The approved drugs in the sarcoma space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.

The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, topical, and subcutaneous formulations.

High-impact upcoming events for drugs in the sarcoma space comprise topline Phase II trial results for SM-88, ADP-A2M4, and RAIN-32; topline Phase Ib/II trial results for ABI-009; and topline Phase III trial results for envafolimab and RAIN-32.

The overall likelihood of approval of a Phase I sarcoma asset is 9.7%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major European markets, while Israel and South Korea share the top spot in Asia.

Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 22 trials each.

Merck & Co leads industry sponsors with the highest overall number of clinical trials for sarcoma, followed by Bristol Myers Squibb and Novartis.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapies

EPIDEMIOLOGY

  • Epidemiological disease definition

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Xpovio for Sarcoma (November 2, 2020)
  • Keytruda for Sarcoma (September 20, 2020)
  • ADP-A2M4 for Sarcoma (May 29, 2020)
  • Tazverik for Sarcoma (December 18, 2019)
  • Tazverik for Sarcoma (December 16, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Tazverik Accelerated Approval: Disease Rarity And Unmet Need Won Out Over Efficacy Concerns
  • Takara Bio's Mipetresgene Autoleucel Receives Orphan Regenerative Medicine Designation For Synovial Sarcoma

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Aadi Licenses Greater China Rights For Cancer Therapy To EOC
  • PharmaMar Licenses Yondelis To TTY In Three Asian Markets

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of sarcoma, 2019-28
  • Figure 2: Incident cases of sarcoma, by age, 2019
  • Figure 3: Incident cases of sarcoma, by tumor type, 2019
  • Figure 4: Overview of pipeline drugs for sarcoma in the US
  • Figure 5: Pipeline drugs for sarcoma, by company
  • Figure 6: Pipeline drugs for sarcoma, by drug type
  • Figure 7: Pipeline drugs for sarcoma, by classification
  • Figure 8: Xpovio for Sarcoma (November 2, 2020): Phase II/III - SEAL
  • Figure 9: Keytruda for Sarcoma (September 20, 2020): Phase II - AcSe
  • Figure 10: Key upcoming events in sarcoma
  • Figure 11: Probability of success in the sarcoma pipeline
  • Figure 12: Clinical trials in sarcoma
  • Figure 13: Top 10 drugs for clinical trials in sarcoma
  • Figure 14: Top 10 companies for clinical trials in sarcoma
  • Figure 15: Trial locations in sarcoma
  • Figure 16: Sarcoma trials status
  • Figure 17: Sarcoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of sarcoma, 2019-28
  • Table 2: Marketed drugs for sarcoma
  • Table 3: Pipeline drugs for sarcoma in the US
  • Table 4: Xpovio for Sarcoma (November 2, 2020)
  • Table 5: Keytruda for Sarcoma (September 20, 2020)
  • Table 6: ADP-A2M4 for Sarcoma (May 29, 2020)
  • Table 7: Tazverik for Sarcoma (December 18, 2019)
  • Table 8: Tazverik for Sarcoma (December 16, 2019)
  • Table 9: Historical global sales, by drug ($m), 2016-20
  • Table 10: Forecasted global sales, by drug ($m), 2021-25
Back to Top
전화 문의
F A Q